Aldevron is a contract development and manufacturing organization, commonly called a CDMO, that produces the biological raw materials used to build gene and cell therapies. Founded in 1998 in Fargo, North Dakota, the company specializes in manufacturing plasmid DNA, messenger RNA, and key proteins such as the Cas9 enzyme used in CRISPR gene editing. While most people have never heard of Aldevron, its products sit upstream of nearly every high-profile gene therapy, mRNA vaccine, and engineered cell treatment in development or on the market today.
The Invisible Supply Layer Behind Gene Therapy
Gene and cell therapies get the headlines, but every one of them depends on a supply chain of specialized biological starting materials. A CAR-T cell therapy that treats leukemia, for instance, requires a lentiviral vector to insert a new gene into a patient’s T cells. That lentiviral vector, in turn, is manufactured using plasmid DNA as its template. The same is true for adeno-associated virus (AAV) vectors used in gene therapies for inherited diseases, and for the mRNA molecules that powered the COVID-19 vaccines. Somebody has to manufacture all of those upstream ingredients at pharmaceutical grade, in facilities that meet strict regulatory standards. That is essentially Aldevron’s business.
Rather than developing its own therapies, Aldevron functions as a supplier to hundreds of biotech and pharmaceutical companies. When a drug developer needs a batch of clinical-grade plasmid DNA to produce viral vectors for a Phase I trial, or research-grade mRNA for preclinical testing, Aldevron is one of the companies they call. This behind-the-scenes role makes Aldevron critically important to the field even though its name rarely appears on approved drug labels. In 2021, Danaher Corporation acquired Aldevron for approximately $9.6 billion, a price tag that reflected how central the company had become to the gene therapy supply chain.
Plasmid DNA Manufacturing
Plasmid DNA is arguably Aldevron’s flagship product and the material most central to its role in gene therapy. A plasmid is a small, circular piece of DNA that can be engineered to carry a therapeutic gene sequence. In the context of gene therapy, plasmids serve as the blueprint from which viral vectors and mRNA are manufactured. If you want to make an AAV vector carrying a gene to treat a genetic eye disease, you start by producing large quantities of the plasmid that encodes that gene. If you want to produce mRNA for a vaccine, the plasmid is the DNA template from which the mRNA is transcribed.
Manufacturing plasmid DNA at pharmaceutical grade is harder than it sounds. The process begins with engineered bacteria, usually strains of E. coli, that carry the desired plasmid. These bacteria are grown in large fermentation vessels, harvested, and then broken open so the plasmid DNA can be extracted. The challenge lies in purification: the raw lysate contains not just the target plasmid but also bacterial chromosomal DNA, RNA, proteins, and endotoxins, all of which must be removed to levels safe for human use. A pharmaceutical-grade plasmid preparation typically needs to hit strict benchmarks, with protein content below a couple of micrograms per milligram of plasmid DNA and endotoxin levels kept very low.1PubMed. Large-scale purification of pharmaceutical-grade plasmid DNA using tangential flow filtration and multi-step chromatography
Purification usually involves multiple chromatographic steps that separate plasmid DNA from contaminants based on size, charge, or other physical properties. Scaling up from a small laboratory batch to the quantities needed for clinical trials introduces additional complications around yield, consistency, and preserving the plasmid’s structural integrity.2PubMed. Scale-Up of Plasmid DNA Downstream Process Based on Chromatographic Monoliths This is the kind of manufacturing know-how that Aldevron has built over more than two decades, and it is why therapy developers outsource this step rather than trying to build the capability in-house.
Cell Banks and the Starting Point of Production
Before a single milligram of plasmid DNA can be produced at scale, the manufacturer needs a reliable starting point: a frozen stock of the bacterial strain carrying the correct plasmid, stored under controlled conditions. In pharmaceutical manufacturing, these frozen stocks are organized into master cell banks and working cell banks. A master cell bank is the original, well-characterized frozen archive. Working cell banks are derived from the master bank and used for routine production runs, so the master is preserved and not depleted.3PubMed. Production of plasmid DNA in industrial quantities according to cGMP guidelines
The stability of these cell banks matters enormously. If the bacteria lose the plasmid over time in storage, or if viability drops, the entire downstream manufacturing process is compromised. Long-term studies of recombinant E. coli master cell banks stored at ultra-low temperatures have shown that both viability and plasmid retention remain stable for over a decade.4PubMed Central. Viability of and plasmid retention in frozen recombinant Escherichia coli over time: a ten-year prospective study That stability is reassuring for companies like Aldevron, which may maintain cell banks for multiple clients across years of clinical development. A therapy that moves slowly through trials still needs its starting material to be identical to what was used in earlier phases.
How Plasmid DNA Feeds Into Viral Vector Production
One of the primary reasons gene therapy developers need plasmid DNA is to produce viral vectors, the delivery vehicles that carry therapeutic genes into a patient’s cells. The two most common types are lentiviral vectors and AAV vectors, and both require plasmid DNA during their manufacturing.
For AAV vectors, the standard production method involves transfecting mammalian cells with multiple plasmids simultaneously. One plasmid carries the therapeutic gene, another provides the structural proteins the virus needs, and a third supplies helper functions. The cells read these plasmid instructions and assemble functional AAV particles. Newer approaches have sought to improve this process. One recent method reduced contamination from residual bacterial DNA by 10- to 50-fold compared to traditional triple transfection, while also increasing the ratio of full, gene-carrying capsids by up to threefold.5PubMed Central. High-purity AAV vector production utilizing recombination-dependent minicircle formation and genetic coupling Improvements like these matter because the purity of the final vector product depends, in part, on the quality of the plasmid DNA that went into making it.
Lentiviral vectors follow a similar logic. They are the workhorse delivery system for CAR-T cell therapies, several of which are already approved and on the market. Tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), and brexucabtagene autoleucel (Tecartus) all use retroviral vectors to insert a chimeric antigen receptor gene into a patient’s T cells, reprogramming those cells to attack cancer.6PubMed Central. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives Every one of those approved therapies required large quantities of high-quality plasmid DNA to manufacture the viral vectors that made the treatment possible. That is the kind of demand that keeps Aldevron’s production lines running.
mRNA and the Enzymes That Make It
Aldevron’s role expanded significantly with the rise of mRNA therapeutics, a platform that became globally visible during the COVID-19 pandemic. Manufacturing mRNA at scale requires two key inputs: a DNA template (the plasmid, again) and a set of specialized enzymes that transcribe the DNA into RNA. Aldevron supplies both.
The transcription process, called in vitro transcription, uses an enzyme to read the plasmid DNA template and produce corresponding mRNA strands. Researchers have used Aldevron-prepared DNA templates in the development of mRNA synthesis platforms.7Oxford Academic. A novel plasmid-based co-tethered transcription platform for high yield, high purity mRNA synthesis Beyond the DNA template itself, Aldevron manufactures the enzymes and other reagents needed for the transcription reaction. The quality of these raw materials directly affects the yield and purity of the final mRNA product, which in turn affects how well a vaccine or therapeutic works when it reaches a patient.
The pandemic underscored how dependent the mRNA vaccine supply chain was on a handful of upstream suppliers. When Pfizer and Moderna needed to produce billions of vaccine doses, the plasmid DNA and enzyme suppliers behind the scenes had to scale up in ways the industry had never attempted before. Aldevron was among the companies thrust into this rapid expansion, and the experience reinforced the broader point that gene therapy manufacturing capacity is only as strong as its weakest upstream link.
CRISPR Gene Editing Components
Gene editing, particularly CRISPR-based editing, represents another area where Aldevron plays a direct role. CRISPR systems require two main components: a guide RNA that directs the editing machinery to the right spot in the genome, and the Cas9 protein that acts as the molecular scissors to cut the DNA at that location. Manufacturing a clinical-grade version of Cas9 protein is not trivial, and Aldevron is one of the companies that produces it.
In a study that manufactured gene-edited antiviral T cells at clinical scale under good manufacturing practice conditions, the researchers used Aldevron’s SpyFi Cas9, described as the GMP version of the widely used HiFi Cas9 protein.8Blood Advances. Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells This particular protein is engineered for high fidelity, meaning it makes fewer unintended cuts at off-target sites in the genome. For a therapy heading into human trials, that precision matters. Any off-target editing could have unpredictable consequences, so clinical protocols demand the highest-quality editing components available.
The approval of the first CRISPR-based therapy, Casgevy, in late 2023 for sickle cell disease and transfusion-dependent beta-thalassemia, signaled that gene editing had moved from the lab to the clinic. As more CRISPR therapies enter clinical trials, demand for GMP-grade Cas9 protein and associated materials is growing. This is a relatively new market for CDMOs, and Aldevron’s early entry gives it a foothold that newer competitors are trying to match.
Quality Control and Analytical Challenges
Manufacturing biological materials for human therapies demands rigorous quality control, and plasmid DNA presents some unique analytical challenges. A plasmid can exist in several topological forms: the desired supercoiled form, which is compact and biologically active, as well as relaxed (open circular) and linear forms that may result from manufacturing stress. Regulators typically want to see a high percentage of supercoiled plasmid in the final product, because the other forms are less effective and may indicate degradation.
Distinguishing these forms from each other requires sensitive analytical methods. Capillary gel electrophoresis has emerged as a particularly effective tool for separating and quantifying different plasmid isoforms, offering better resolution and quantitation accuracy than older methods like agarose gel electrophoresis or ion exchange chromatography.9PubMed. A platform method for plasmid isoforms analysis by capillary gel electrophoresis For a company like Aldevron, which ships plasmid DNA to clients who will use it in regulated manufacturing processes, having robust analytical methods to confirm product identity, purity, and structural integrity is not optional. It is the basis on which regulatory filings rest.
Beyond topology, quality testing includes checking for residual host cell proteins, endotoxins, residual RNA, and confirming that the DNA sequence is correct. Each of these measurements requires its own validated assay, and the specifications can vary depending on whether the plasmid is headed for research use, preclinical studies, or a clinical trial in human patients. The gap between “research grade” and “GMP grade” is enormous in terms of documentation, testing, and cost.
Supply Chain Pressures in Gene and Cell Therapy
The gene therapy field has grown fast enough that supply chain bottlenecks are a real and recurring problem. When dozens of clinical programs all need GMP-grade plasmid DNA, mRNA, or viral vectors, the handful of CDMOs with the capacity and regulatory standing to produce these materials can become overbooked. Lead times stretch. Costs rise. And therapy developers, especially smaller biotech companies, find themselves competing for manufacturing slots.
Managing this supply chain requires more than just adding production capacity. The biological materials used in gene and cell therapy are inherently variable, and sourcing them from a single supplier creates risk. Industry guidance increasingly emphasizes dual sourcing, deep technical assessments of supplier capabilities, and proactive planning that begins early in clinical development rather than scrambling at Phase III.10International Journal of Medical Science and Pharmaceutical Research. Supplier Quality Reinvented: Managing High‑Risk Raw Materials and Global Supply Chain Instability in Cell & Gene Therapy Geographic diversification of manufacturing also matters: a facility disruption at a single site can delay multiple clinical programs if there is no backup.
Aldevron’s position as one of the largest dedicated plasmid DNA and mRNA manufacturers means it carries a disproportionate share of the field’s supply chain risk. The Danaher acquisition gave the company access to greater capital for expansion, but the fundamental challenge remains: building biomanufacturing capacity takes years, and demand from new gene therapy programs continues to accelerate.
Next-Generation Plasmid Technologies
Traditional plasmids carry some baggage. A conventional plasmid includes not just the therapeutic gene but also a bacterial backbone containing elements like an antibiotic resistance gene, which is used during manufacturing to ensure the bacteria retain the plasmid. That resistance gene serves no purpose in the final therapeutic product and raises theoretical safety concerns if the DNA were to integrate into a patient’s genome or transfer to gut bacteria. Regulatory agencies have flagged antibiotic resistance markers as undesirable in clinical-grade plasmids.
This has driven development of next-generation plasmid formats. One example is the Nanoplasmid vector, which features a smaller backbone and uses an antibiotic-free selection method instead of a resistance gene. Studies have shown that these minimized plasmid vectors offer both a greater safety profile and improved efficiency compared to traditional plasmids across a range of applications.11PubMed Central. Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors A smaller backbone means a higher proportion of the DNA molecule is devoted to the therapeutic payload, which can translate to better gene expression in the target cells. It also means less bacterial DNA contaminating the final product.
Aldevron has been involved in the development and manufacturing of these newer plasmid formats, positioning itself not just as a producer of conventional plasmids but as a company tracking the technology as it evolves. For therapy developers, adopting a next-generation plasmid format is not a trivial switch; it can require reformulating the entire manufacturing process from cell banking through purification. But the potential benefits in safety and performance are pushing the field in that direction.
Where Aldevron Fits in a Changing Industry
The CDMO landscape for gene and cell therapy is more crowded than it was a decade ago, but it remains concentrated. A handful of companies handle the majority of GMP plasmid DNA and mRNA manufacturing, and Aldevron is among the largest. Its product range spans the three main categories that gene therapy developers need: plasmid DNA, mRNA, and proteins like Cas9. Few competitors offer all three under one roof with established regulatory track records.
The commercial dynamics of this market are unusual. Unlike a traditional pharmaceutical CDMO that manufactures finished drug products, Aldevron’s customers are themselves manufacturers. A company producing a CAR-T therapy buys plasmid DNA from Aldevron, uses it to make lentiviral vectors at its own facility or at another CDMO, and then uses those vectors to engineer patient T cells. Aldevron sits two or three steps upstream of the patient, which makes its role less visible but no less critical. A quality failure or supply interruption at the plasmid DNA level cascades forward through every downstream step.
The expansion of approved gene therapies, the continued growth of the mRNA platform beyond vaccines into areas like cancer immunotherapy and rare disease treatment, and the clinical maturation of CRISPR-based medicines all point toward sustained demand for Aldevron’s core products. Whether the company’s capacity and technology keep pace with that demand is one of the real bottleneck questions facing the field over the next decade.